Introduction
Breast cancer (BCa) remains a leading cause of cancer-related mortality globally. While therapeutic strategies have advanced, the molecular mechanisms driving tumor proliferation, migration, and invasion are not yet fully understood. Recent research has highlighted the critical role of non-coding RNAs—specifically the interaction between long non-coding RNAs (lncRNAs) and microRNAs (miRNAs)—in cancer pathogenesis. This study investigates the KCNQ1OT1/miR-935 axis, exploring how the lncRNA KCNQ1OT1 regulates miR-935 to drive BCa progression and its potential as a diagnostic biomarker.
Methods
The researchers employed a multi-faceted approach combining in vitro cell culture experiments and clinical patient data:
- Expression Analysis: Quantitative real-time PCR (qRT-PCR) was used to measure RNA levels in four BCa cell lines (MCF-7, MDA-MB-231, BT474, T47D) and one normal mammary epithelial line (MCF-10A).
- Interaction Validation: A Luciferase Reporter Assay was used to physically confirm that KCNQ1OT1 binds directly to the "seed sequence" of miR-935.
- Functional Assays: Cell proliferation was measured via CCK-8 assays, while the ability of cells to migrate and invade through a membrane was evaluated using Transwell assays.
- Clinical Correlation: Serum samples from 124 BCa patients and 62 healthy controls were analyzed to determine clinical relevance.
- Diagnostic Modeling: Receiver Operating Characteristic (ROC) curves were utilized to calculate the Area Under the Curve (AUC), a standard metric for diagnostic accuracy.
Results
The KCNQ1OT1/miR-935 "Sponge" Mechanism
The study confirmed that KCNQ1OT1 is significantly elevated in BCa cells, while miR-935 expression is decreased. KCNQ1OT1 functions as an oncogene by acting as a molecular "sponge," sequestering miR-935 and preventing it from performing its natural role as a tumor suppressor. A striking negative correlation (r = -0.867) was found between KCNQ1OT1 and miR-935 levels in patient serum, indicating that as the lncRNA increases, the tumor-suppressive miRNA decreases.
Impact on Tumor Progression
Functional assays demonstrated that overexpressing miR-935 significantly inhibited the proliferation, migration, and invasion of BCa cells (P < 0.05). Crucially, the growth-promoting effects of KCNQ1OT1 were "remarkably reversed" when miR-935 was reintroduced into the cells. This proves that KCNQ1OT1 exerts its oncogenic influence specifically through the inhibition of this miRNA axis.
Diagnostic Accuracy
The clinical significance of these findings was highlighted by ROC analysis. While KCNQ1OT1 (AUC = 0.900) and miR-935 (AUC = 0.919) were effective biomarkers individually, their combination provided superior diagnostic power. The combined axis achieved an AUC of 0.991, with a sensitivity of 95.4% and a specificity of 91.2%, indicating near-perfect accuracy for clinical screening.
Discussion and Conclusion
This research identifies the KCNQ1OT1/miR-935 axis as a key regulatory pathway in breast cancer. By inhibiting miR-935, KCNQ1OT1 facilitates the aggressive biological processes of BCa cells. These findings suggest that measuring serum levels of these non-coding RNAs could serve as a powerful, non-invasive diagnostic tool.
While these results are promising, future work is needed to validate these effects in animal models and to explore the specific downstream messenger RNA (mRNA) targets of miR-935, such as the AKT pathway, to further elucidate the therapeutic potential of this axis across diverse patient populations.
Summary updated